- Home
- LXRX vs RCKT Comparison
LXRX vs RCKT Comparison
Compare LXRX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXRX
- RCKT
- Stock Information
- Founded
- LXRX 1995
- RCKT 1999
- Country
- LXRX United States
- RCKT United States
- Employees
- LXRX N/A
- RCKT N/A
- Industry
- LXRX Biotechnology: Pharmaceutical Preparations
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- LXRX Health Care
- RCKT Health Care
- Exchange
- LXRX Nasdaq
- RCKT Nasdaq
- Market Cap
- LXRX 228.8M
- RCKT 264.0M
- IPO Year
- LXRX 2000
- RCKT N/A
- Fundamental
- Price
- LXRX $1.08
- RCKT $2.99
- Analyst Decision
- LXRX Buy
- RCKT Buy
- Analyst Count
- LXRX 4
- RCKT 13
- Target Price
- LXRX $3.67
- RCKT $18.50
- AVG Volume (30 Days)
- LXRX 5.0M
- RCKT 3.8M
- Earning Date
- LXRX 07-31-2025
- RCKT 08-04-2025
- Dividend Yield
- LXRX N/A
- RCKT N/A
- EPS Growth
- LXRX N/A
- RCKT N/A
- EPS
- LXRX N/A
- RCKT N/A
- Revenue
- LXRX $31,213,000.00
- RCKT N/A
- Revenue This Year
- LXRX N/A
- RCKT N/A
- Revenue Next Year
- LXRX N/A
- RCKT N/A
- P/E Ratio
- LXRX N/A
- RCKT N/A
- Revenue Growth
- LXRX 1251.21
- RCKT N/A
- 52 Week Low
- LXRX $0.28
- RCKT $2.19
- 52 Week High
- LXRX $2.45
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- LXRX 66.94
- RCKT 45.55
- Support Level
- LXRX $0.84
- RCKT $2.76
- Resistance Level
- LXRX $1.19
- RCKT $3.24
- Average True Range (ATR)
- LXRX 0.09
- RCKT 0.19
- MACD
- LXRX 0.02
- RCKT 0.17
- Stochastic Oscillator
- LXRX 76.60
- RCKT 74.85
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.